Why do some people respond better to GLP-1 drugs? Gut microbiome may hold clues

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment outcomes. The authors conclude that microbiome changes seen during therapy are most likely driven by diet, behavior, and weight loss, although microbial profiling may eventually help predict patient responses.

Vaginal microbiome may play key role in pregnancy health and preterm birth risk, researchers say

Researchers reviewed evidence linking the vaginal microbiome to pregnancy health and spontaneous preterm birth, highlighting how Lactobacillus-dominated communities help maintain immune balance and vaginal acidity. Dysbiosis and inflammatory signaling may contribute to preterm birth risk, while emerging microbiome-targeted therapies aim to restore protective microbial ecosystems.

Patellar osteochondral fracture, loose body in instability

A 16-year-old female high school junior with a history of recurrent patellar instability presented with left knee pain following a patellar dislocation event.
Two weeks earlier, she stepped onto a slippery deck, causing her left knee to twist internally and her patella to dislocate laterally. After the incident, she reported that her patella spontaneously reduced, but she had been unable to ambulate afterward due to pain, swelling and a sensation of patellar instability. Prior treatments for her patellar instability included anti-inflammatory medications, crutches, bracing, rest, activity

Bimatoprost implant reduces IOP, improves vision at 12 months

Editor’s note: This is a developing news story. Please check back soon for updates.
At 12 months in a phase 1/2 trial, the Bimatoprost Drug Pad-IOL System improved IOP, vision and treatment burden in patients with open-angle glaucoma or ocular hypertension with concomitant cataract.
According to a press release from SpyGlass Pharma, 104 patients were randomly assigned 2:1:1 to receive 78 µg Bimatoprost Drug Pad-IOL System (BIM-IOL System) (51 patients) with daily administration of artificial tear drops, 39 µg BIM-IOL System (23 patients) with daily administration of artificial tear drops, or

FDA approves Cosentyx for pediatric hidradenitis suppurativa

The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.
The approval makes secukinumab (Cosentyx) the first IL-17A inhibitor approved for a pediatric population.
“Hidradenitis suppurativa often begins in adolescence and can cause irreversible scarring and disabilities,” Alexa B. Kimball, MD, MPH, lead investigator of the SUNSHINE and SUNRISE clinical trials in adult HS patients, president and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center and

Top 10 practice takeaways from 2026 dyslipidemia guideline

Dyslipidemia is highly prevalent and the primary direct driver of atherosclerotic CVD.
In the more than 7 years since the last American Heart Association/American College of Cardiology/Multisociety Cholesterol guideline, there have been major advances in tests, tools and treatments to target dyslipidemia for improvement in CV health.
The newly released 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia incorporates these updates and the latest evidence into a comprehensive document featuring 18 easy-to-follow figures and 27 tables across more than 90 pages of evidence-based